The fibroblast growth factor receptor (FGFR) family consists of transmembrane receptor tyrosine kinases that regulate a broad range of biological processes, including embryonic development, wound healing, and angiogenesis. Upon binding of FGFs (fibroblast growth factors) to their corresponding FGFRs, downstream signaling pathways—such as RAS-RAF-MAPK, PI3K-AKT/mTOR, STATs, and PLCγ/PKC—are activated, orchestrating cellular proliferation, survival, migration, and differentiation. In oncology, abe

The year 2024 marked an unprecedented boom in the field of antibody-drug conjugates (ADCs). With multiple innovative drugs advancing smoothly from Phase III clinical trials to regulatory review and market approval, the outlook for cancer treatment has become increasingly promising. These breakthrough ADCs have not only demonstrated remarkable efficacy and safety profiles but have also provided more personalized and precise therapeutic options for patients with various types of cancer. Whether ta

At the forefront of cancer treatment, scientists are continually exploring new targets and therapeutic strategies to address this global health challenge. B7-H3 (CD276), a type I transmembrane glycoprotein, has garnered significant attention due to its overexpression in a wide range of human cancers. Initially believed to function as a T-cell costimulatory molecule, B7-H3 has since been found to possess complex immunomodulatory properties, capable of both promoting and suppressing immune respons

June 04, 2025 -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. (“Cook MyoSite”) to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-F

Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. June 04, 2025 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the “Note”) with existing investor, GKCC, LLC (“Note Holder” or “GKCC”) (the “Note Financing”

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 June 02, 2025 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (bevacizumab gamma) is now commercially ava

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in preclinical studies --Investigational New Drug (IND)-enabling activities ongoing to support IND submission later this year June 02, 2025 -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory diseas

Japan’s intellectual property community recently witnessed a landmark court ruling. On May 27, 2025, the Intellectual Property High Court of Japan issued a judgment in the patent infringement case involving Toray Industries' antipruritic drug Remitch® (Nalfurafine). The court ordered Sawai Group and Fuso Pharmaceutical to pay damages of ¥14.29 billion (~$100 million) and ¥7.47 billion (~$50 million) respectively. The combined total of approximately $150 million marks the highest damages ever awa

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63%

- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - June 02, 2025 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a randomized, double-blind, placebo-